Philadelphia-area companies announced 33 acquisitions across the world during 2024 with two valued at more than $1 billion ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

of retina specialists. Cencora (COR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

When it comes to protecting your eyesight, it turns out the secret ingredient might already be sitting in your kitchen. Eye ...

Arogya Aarohan app & other AI-driven tools are being tested for early detection of diseases as part of Rs 300-cr initiative ...

Another is to surgically implant them onto the retina using a piece of synthetic or natural material ... current and future therapeutic agents and practical considerations for retinal specialists.

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...

DNA Damage Is Key Factor in Age-Related Macular Degeneration Dec. 3, 2024 — A research team has discovered that accumulated DNA damage in the retina is a key contributor to age-related macular ...